HBV感染合并代谢综合征的诊治

刘静; 施军平

doi:10.3969/j.issn.1001-5256.2016.11.004

HBV感染合并代谢综合征的诊治

DOI: 10.3969/j.issn.1001-5256.2016.11.004

刘静,
施军平

杭州师范大学附属医院肝病科

基金项目:

杭州市卫生计生科技计划重大项目(2015ZD02)；

详细信息

中图分类号: R512.62;R589
计量
- 文章访问数: 2435
- HTML全文浏览量: 15
- PDF下载量: 467
- 被引次数: 0
出版历程
- 出版日期: 2016-11-20

Diagnosis and treatment of hepatitis B virus infection complicated by metabolic syndrome

Department of Hepatology, The Affiliated Hospital of Hangzhou Normal University

Research funding:

摘要

摘要:
随着肥胖在全球的流行,HBV感染合并代谢综合征(MS)的发病率逐年升高,成为慢性HBV感染者中的一类特殊人群,对其疾病特征、诊治策略的研究也是近年肝病领域的热点之一。MS不仅增加慢性乙型肝炎(CHB)患者肝纤维化和肝硬化的风险,还可降低抗病毒治疗的应答。因此对于HBV感染者,尤其是抗病毒治疗应答不佳的CHB患者,应考虑是否合并有MS及其组分;对HBV感染合并MS患者应积极进行肝硬化相关的筛查和监测,指导制订合适的治疗方案。
- 肝炎病毒,乙型 /
- 代谢综合征 /
- 诊断 /
- 治疗
Abstract:
With the prevalence of obesity around the world,the incidence rate of hepatitis B virus( HBV) infection complicated by metabolic syndrome( MS) is increasing year by year,and such patients have become a special population in patients with chronic HBV infection. In recent years,the research on the features of this disease and diagnosis and treatment strategies has become a hot topic in the field of liver disease. MS not only increases the risk of liver fibrosis and cirrhosis in chronic hepatitis B( CHB) patients,but also reduces the response to antiviral therapy. Therefore,as for patients with HBV infection,especially CHB patients with suboptimal response to antiviral therapy,MS and its components should be considered. Screening and monitoring of liver cirrhosis should be performed for patients with HBV infection complicated by MS to guide the development of proper treatment regimens.
- hepatitis B virus /
- metabolic syndrome /
- diagnosis /
- therapy

HTML全文

参考文献(28)

[1] Chinese Society of Hepatology,Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版)[J].临床肝胆病杂志,2015,31(12):1941-1960.

[2]WONG GL,WONG VW,CHOI PC,et al.Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B[J].Gut,2009,58(1):111-117.

[3]HA M,XIA W,TANG D,et al.Hepatitis B e antigen-positive and high levels of alanine aminotransferase are associated with prevalence of metabolic syndrome in chronic HBV patients[J].Obes Res Clin Pract,2015.[Epub ahead of print]

[4]LI WC,LEE YY,CHEN IC,et al.Association between the hepatitis B and C viruses and metabolic diseases in patients stratified by age[J].Liver Int,2013,33(8):1194-1202.

[5]CHUNG TH,KIM MC,KIM CS.Association between hepatitis B surface antigen seropositivity and metabolic syndrome[J].Korean J Fam Med,2014,35(35):81-89.

[6]JINJUVADIA R,LIANGPUNSAKUL S.Association between metabolic syndrome and its individual components with viral hepatitis B[J].Am J Med Sci,2014,347(1):23-27.

[7]HUANG CY,LU CW,LIU YL,et al.Relationship between chronic hepatitis B and metabolic syndrome:a structural equation modeling approach[J].Obesity,2016,24(2):483-489.

[8]JARCUSKA P,JANICKO M,KRUZLIAK P,et al.Hepatitis B virus infection in patients with metabolic syndrome:a complicated relationship.Results of a population based study[J].Eur J Intern Med,2014,25(3):286-291.

[9]ZHOU Y,CUI Y,DENG H,et al.Association between hepatitis B virus infection and metabolic syndrome:a retrospective cohort study in Shanghai,China[J].BMC Public Health,2014,14(1):516.

[10]KATOONIZADEH A,GHOROGHI S,SHARAFKHAH M,et al.Chronic hepatitis B infection is not associated with increased risk of vascular mortality while having an association with metabolic syndrome[J].J Med Virol,2016,88(7):1230-1237.

[11]TARGHER G,BERTOLINI L,PADOVANI R,et al.Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C[J].J Hepatol,2007,46(6):1126-1132.

[12]PAPATHEODORIDIS GV,MANESIS EK,MANOLAKOPOULOS S,et al.Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?[J].Hepatology,2008,48(5):1451-1459.

[13]CHENG YL,WANG YJ,KAO WY,et al.Inverse association between hepatitis B virus infection and fatty liver disease:a large-scale study in populations seeking for check-up[J].PLoS One,2013,8(8):903-906.

[14]WONG VW,WONG GL,CHU WC,et al.Hepatitis B virus infection and fatty liver in the general population[J].J Heptol,2012,56(3):533-540.

[15]MACHADO MV,OLIVEIRA AG,CORTEZ-PINTO H.Hepatic steatosis in hepatitis B virus infected patients:meta-analysis of risk factors and comparison with hepatitis C infected patients[J].J Gastroenterol Hepatol,2011,26(9):1361-1367.

[16]WU YL,PENG XE,ZHU YB,et al.Hepatitis B virus X protein induces hepatic steatosis by enhancing the expression of liver fatty acid binding protein[J].J Virol,2015,90(4):1729-1740.

[17]TURATI F,TALAMINI R,PELUCCHI C,et al.Metabolic syndrome and hepatocellular carcinoma risk[J].Br J Cancer,2013,108(1):222-228.

[18]MENAA,PEDREIRA JD,CASTRO A,et al.Metabolic syndrome association with fibrosis development in chronic hepatitis B virus inactive carriers[J].J Gastroenterol Hepatol,2014,29(1):173-178.

[19]ZHANG F,ZHANG Z,KONG D,et al.Tetramethyl pyrazine reduces glucose and insulin—induced activation of hepatic stellate cells by inhibiting insulin receptor-mediated P13K/AKT and ERK pathways[J].Mol Cell Endocrinol,2014,382(1):197-204.

[20]ZHANG RN,PAN Q,ZHANG Z,et al.Saturated fatty acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic fatty liver disease by Toll-Like receptor 4-mediated innate immune response[J].Hepat Mon,2015,15(5):e27909.

[21]Expert Committee on the Diagnosis and Management of Nonalcoholic Fatty Liver Disease.Recommendation for the standardization of diagnosis and treatment of fatty liver disease[J].J Clin Hepatol,2013,29(9):207-209.(in Chinese)中国医师协会脂肪性肝病专家委员会.脂肪性肝病诊疗规范化的专家建议[J].临床肝胆病杂志,2013,29(9):207-209.

[22]MALIK R,AFDHAL N.Stiffness and impedance:the new liver biomarkers[J].Clin Gastroenterol Hepatol,2007,5(10):1144-1146.

[23]European Association for the Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.

[24]CAVIGLIA GP,ABATE ML,PELLICANO R,et al.Chronic hepatitis B therapy:available drugs and treatment guidelines[J].Minerva Gastroenterol Dietol,2015,61(2):61-70.

[25]VALLET-PICHARD A,POL S.Hepatitis B virus treatment beyond the guidelines:special populations and consideration of treatment withdrawal[J].Therap Adv Gastroenterol,2014,7(4):148-155.

[26]NEWSOME PN,ALLISON ME,ANDREWS PA,et al.Guidelines for liver transplantation for patients with non-alcoholic steato hepatitis[J].Gut,2012,61(4):484-500.

[27]GONG L,LIU J,WANG J,et al.Hepatic steatosis as a predictive factor of antiviral effect of pegylated interferon therapy in patients with hepatitis B[J].Transplant Proc,2015,47(10):2886-2891.

[28]SHI JP,FAN JG,WU R,et al.Prevalence and risk factors of hepatic steatosis and its impact on liver injure in Chinese patients with chronic hepatitis B[J].J Gastroenterol Hepatol,2008,23(9):1419-1425.

施引文献

资源附件(0)

访问统计